HIPEC for Peritoneal Mesothelioma: Survival
CRS/HIPEC reached a 39-month median survival in a 111-patient single-center series, and 53 months in a 405-patient multi-institutional study.
HIPEC: A Leading Treatment for Peritoneal Mesothelioma
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is among the most effective treatments for peritoneal mesothelioma. Long-term data from a 28-year, 111-patient single-center series shows survival curves flattening after year 6. The study’s authors describe this as a finding that may point to long-term disease control for some patients, while stopping short of calling the disease cured.
28-year outcome data (111 patients treated 1993-2021):
- Survival curves flatten after postoperative year 6, a pattern that may point to long-term disease control for some patients
- Median survival: 39.0 months for the full cohort
- Median survival: 127 months for patients who achieved complete cytoreduction (R0-R1, no visible residual disease)
Separately, a 405-patient multi-institutional study (Yan et al., J Clin Oncol, 2009) reported:
- Median survival: 53 months
- 5-year survival: 47%
What Is CRS/HIPEC?
The Procedure
CRS/HIPEC is a two-part surgical treatment:
1. Cytoreductive Surgery (CRS)
- Removal of all visible tumors from the abdominal cavity
- May include removal of affected peritoneum, organs, or organ portions
- Goal: Complete cytoreduction (CC-0 = no visible disease remaining)
2. Heated Intraperitoneal Chemotherapy (HIPEC)
- Immediately follows surgery while abdomen is still open
- Heated chemotherapy (104-109 degrees Fahrenheit) circulated through abdominal cavity
- Duration: 60-120 minutes
- Heat enhances chemotherapy penetration and effectiveness
Why It Works
The combination addresses peritoneal mesothelioma on multiple levels:
- Surgery removes bulk disease that chemotherapy cannot penetrate
- Heat kills microscopic cancer cells and enhances drug absorption
- Direct chemotherapy delivery reaches cells that systemic chemo cannot access
- High drug concentrations possible without systemic toxicity
Survival Outcomes by Center
High-Volume Center Data (28 Years)
A study of 111 consecutive patients treated from 1993-2021 showed:
| Time Point | Median Survival |
|---|---|
| Overall cohort | 3.3 years (39.0 months) |
| If survived 1 year | 4.9 years |
| If survived 3 years | 6.1 years |
| 75th percentile | 10.6 years |
Conditional survival improves significantly for patients who reach post-operative milestones.
Australian Centre Outcomes
Data from 53 months median follow-up:
| Measure | Outcome |
|---|---|
| Median overall survival | 53 months |
| 1-year survival | 76% |
| 3-year survival | 55% |
| 5-year survival | 49% |
Survival by Completeness of Cytoreduction
The degree of tumor removal is the strongest predictor of outcomes:
The 111-patient single-center series above classified resection status as R0-R1, R2a, R2b, and R2c rather than the older CC-0/CC-1/CC-2 scale. Its reported outcomes by resection status:
| Resection Status | Definition | Median Survival |
|---|---|---|
| R0-R1 | Complete cytoreduction, no visible residual disease | 127 months |
| R2a | Residual disease under 5mm | 35.9 months |
| R2b | Residual disease 5-20mm | 11.4 months |
| R2c | Residual disease over 20mm | 3.0 months |
Complete cytoreduction (R0-R1) reached a 127-month median survival (about 10.6 years) in this series.
Prognostic Factors
Tumor Burden (PCI Score)
The Peritoneal Cancer Index (PCI) measures disease extent on a 0-39 scale:
| PCI Range | Median Survival |
|---|---|
| 0-20 (low-moderate) | 103 months |
| 21-39 (high) | 33 months |
Other Significant Factors
Favorable factors:
- Complete cytoreduction (CC-0)
- Low PCI score (under 20)
- No lymph node involvement
- Epithelioid cell type
- Low proliferative index
- Negative podoplanin
Unfavorable factors:
- High PCI score
- Incomplete cytoreduction
- Lymph node metastasis
- Sarcomatoid or biphasic histology
- High proliferative markers
Long-Term Survivors: What Doctors Can and Cannot Say
Some people treated with CRS/HIPEC live many years. The 28-year series tracked how survival odds shift as people pass each post-operative milestone:
| Finding | Data |
|---|---|
| Survival curve plateau | After postoperative year 6 |
| Conditional survival at 1 year | 4.9 years median |
| Conditional survival at 3 years | 6.1 years median |
The overall and conditional survival curves flatten after year 6. In their discussion, the study’s authors say that pattern suggests long-term cure for some of these people. They stop short of declaring anyone cured, and they didn’t measure a cure rate. They also recommend survivors continue long-term follow-up and surveillance imaging, less aggressively than before.
No study has established a cure rate for peritoneal mesothelioma. In the 28-year series, the survival curve stops falling after about year 6. Researchers say that pattern may point to long-term disease control. About two-thirds of people treated with CRS/HIPEC still see the cancer return, and recurrence doesn’t rule out more treatment.
Recurrence Patterns
A 2025 study in Annals of Surgical Oncology examined recurrence risk:
- Two-thirds of patients experience recurrence at some point
- Recurrence doesn’t preclude additional treatment
- Iterative CRS/HIPEC possible for selected recurrences
- Systemic chemotherapy options available
Options if the Cancer Comes Back
For patients who recur:
- Repeat cytoreduction may be possible
- Second HIPEC in select cases
- Systemic immunotherapy options
- Palliative care for symptom management
Neoadjuvant Therapy: Emerging Approach
A March 2026 study showed that systemic therapy before CRS/HIPEC for high-volume disease is:
- Feasible and safe
- Similar operative times as upfront surgery
- Comparable complication rates
- May improve resectability of initially borderline cases
This approach allows some patients with higher-volume disease to become surgical candidates.
Who Is a Candidate?
Who Benefits Most From CRS/HIPEC
- Diagnosis confirmed as peritoneal mesothelioma
- Low to moderate tumor burden (PCI under 20)
- Good performance status (able to tolerate major surgery)
- No distant metastases
- Epithelioid cell type preferred
When Surgery May Not Be Appropriate
- Very high tumor burden (PCI over 30)
- Poor functional status
- Significant comorbidities
- Certain tumor locations (diffuse small bowel involvement)
- Aggressive sarcomatoid histology
How Centers Decide Who Qualifies
Candidacy is determined through:
- CT/MRI imaging of abdomen and pelvis
- Possible diagnostic laparoscopy
- Assessment of tumor volume and distribution
- Pathology review of biopsy
- Cardiopulmonary evaluation
- Nutritional assessment
Recovery and Expectations
Hospital Stay
- Typical stay: 7-14 days
- ICU monitoring first 1-2 days
- Gradual return of bowel function
- Pain management required
The First Months Home
- Return to light activity: 4-6 weeks
- Full recovery: 2-3 months
- Long-term dietary modifications may be needed
- Regular follow-up imaging required
Potential Complications
CRS/HIPEC is major surgery with potential risks:
- Anastomotic leak
- Infection
- Bowel obstruction
- Kidney effects from chemotherapy
- Blood clots
- Wound healing issues
Complication rates are lower at high-volume specialized centers.
Finding a HIPEC Center
What to Look For
- High case volume (minimum 20-30 cases per year)
- Multidisciplinary team (surgical oncologist, medical oncologist, pathologist)
- Experience with mesothelioma specifically (not just other peritoneal cancers)
- Published outcomes data
Questions to Ask
- How many peritoneal mesothelioma cases have you treated?
- What is your complete cytoreduction rate?
- What is your median survival for mesothelioma specifically?
- What is your complication rate?
- Do you offer repeat surgery for recurrence?
Comparison to Other Treatments
| Treatment | Median Survival |
|---|---|
| CRS/HIPEC, full cohort (111-patient series) | 39 months |
| CRS/HIPEC, complete cytoreduction, R0-R1 (same series) | 127 months |
| Systemic chemotherapy alone | 12-14 months |
| Palliative care | 6-9 months |
CRS/HIPEC offers 3-10x longer survival than chemotherapy alone for eligible patients, depending on how completely the tumor is removed.
Reader Q&A
Frequently Asked Questions
What is the cure rate for CRS/HIPEC?
There is no established cure rate for CRS/HIPEC in peritoneal mesothelioma. In the largest single-center series (111 patients over 28 years), survival curves flatten after about 6 years post-surgery, a pattern the study’s authors say may point to long-term disease control for some patients. People who achieve complete cytoreduction (R0-R1, no visible residual disease) have the best outcomes in that series, with a median survival of 127 months.
How long is recovery from CRS/HIPEC?
Hospital stay is typically 7-14 days. Return to light activity takes 4-6 weeks, with full recovery in 2-3 months. Long-term dietary modifications may be needed.
Who is a good candidate for CRS/HIPEC?
Ideal candidates have peritoneal mesothelioma with low-moderate tumor burden (PCI under 20), good performance status, epithelioid cell type, and no distant metastases. A surgical evaluation at a high-volume center determines candidacy.
What if the cancer recurs after HIPEC?
About two-thirds of patients experience recurrence. Options include repeat cytoreduction, second HIPEC in select cases, systemic immunotherapy, and palliative care. Recurrence doesn’t preclude additional treatment.
What is the life expectancy of someone with peritoneal mesothelioma?
People with peritoneal mesothelioma had a median survival of 53 months with cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) in the 405-patient multi-institutional study, compared to 6-12 months without treatment. In that same study, 5-year survival was 47%. Survival varies by cell type, with epithelioid averaging over 31 months and sarcomatoid around 5 months after treatment.
How close are we to a cure for mesothelioma?
No cure exists for mesothelioma as of 2026. Approved first-line treatments include nivolumab plus ipilimumab immunotherapy (FDA-approved, with 3-year PFS of 14% vs. 1% for chemotherapy) and pembrolizumab plus chemotherapy (ORR 22% vs. 6%). Over 80 active clinical trials test emerging therapies like enzyme therapy (ADI-PEG20 extended survival 4-fold at 3 years), cancer vaccines (UV1 doubled response rates), and targeted therapies, with median survival reaching 18+ months in some multimodal approaches. Research shows improved outcomes but no evidence of curative potential yet.